Biocorrx (OTCMKTS:BICX) Releases Earnings Results, Beats Estimates By $0.03 EPS

Biocorrx (OTCMKTS:BICX) posted its quarterly earnings data on Friday. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03, Zacks reports. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.22 million.

Biocorrx Stock Performance

BICX stock traded up $0.09 during trading on Friday, reaching $0.49. The company had a trading volume of 27,821 shares, compared to its average volume of 577. The firm has a 50-day simple moving average of $0.37 and a 200-day simple moving average of $0.36. The company has a market cap of $14.36 million, a price-to-earnings ratio of -3.09 and a beta of 0.17. Biocorrx has a twelve month low of $0.20 and a twelve month high of $1.28.

About Biocorrx

BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.